PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

This commercially supported Virtual Satellite Product Theater is independent of the American Academy of Otolaryngic Allergy (AAOA) educational activities and is not accredited by AAOA.

DISCLOSURE OF COMMERCIAL SUPPORT

This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.

PROGRAM OVERVIEW

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a significant health burden, affecting about 25% to 30% of the 28.9 million US adults with chronic rhinosinusitis. These patients face increased risk of comorbidities, frequent need for functional endoscopic sinus surgery, and overreliance on oral corticosteroids. Moreover, many continue to have poor symptom control and impaired quality of life, often reporting poor sleep, depression, and social withdrawal despite standard care.

Join our expert faculty as they discuss recommended patient assessment, current evidence on the safety and efficacy of available treatments, strategies for individualized treatment selection, and approaches to overcome barriers to optimal use of biologics.

CRSwNP in Focus: Evidence-Based Strategies for Assessment and Treatment Decision-Making - Wednesday, September 17, 2025